Peter McErlean1, Christopher G Bell2, Richard J Hewitt1,3, Zabreen Busharat1, Patricia P Ogger1, Poonam Ghai1, Gesa J Albers1, Emily Calamita1, Shaun Kingston3, Philip L Molyneaux1,3, Stephan Beck4, Clare M Lloyd1, Toby M Maher1,3,5,6, Adam J Byrne1. 1. National Heart and Lung Institute, Imperial College London, London, United Kingdom. 2. William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom. 3. National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom. 4. Department of Cancer Biology, University College London Cancer Institute, University College London, London, United Kingdom; and. 5. Hastings Centre for Pulmonary Research and. 6. Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Abstract
Rationale: Airway macrophages (AMs) are key regulators of the lung environment and are implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal respiratory disease with no cure. However, knowledge about the epigenetics of AMs in IPF is limited. Objectives: To assess the role of epigenetic regulation of AMs during lung fibrosis. Methods: We undertook DNA methylation (DNAm) profiling by using Illumina EPIC (850k) arrays in sorted AMs from healthy donors (n = 14) and donors with IPF (n = 30). Cell-type deconvolution was performed by using reference myeloid-cell DNA methylomes. Measurements and Main Results: Our analysis revealed that epigenetic heterogeneity was a key characteristic of IPF AMs. DNAm "clock" analysis indicated that epigenetic alterations in IPF AMs were not associated with accelerated aging. In differential DNAm analysis, we identified numerous differentially methylated positions (n = 11) and differentially methylated regions (n = 49) between healthy and IPF AMs, respectively. Differentially methylated positions and differentially methylated regions encompassed genes involved in lipid (LPCAT1 [lysophosphatidylcholine acyltransferase 1]) and glucose (PFKFB3 [6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3]) metabolism, and importantly, the DNAm status was associated with disease severity in IPF. Conclusions: Collectively, our data identify that changes in the epigenome are associated with the development and function of AMs in the IPF lung.
Rationale: Airway macrophages (AMs) are key regulators of the lung environment and are implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal respiratory disease with no cure. However, knowledge about the epigenetics of AMs in IPF is limited. Objectives: To assess the role of epigenetic regulation of AMs during lung fibrosis. Methods: We undertook DNA methylation (DNAm) profiling by using Illumina EPIC (850k) arrays in sorted AMs from healthy donors (n = 14) and donors with IPF (n = 30). Cell-type deconvolution was performed by using reference myeloid-cell DNA methylomes. Measurements and Main Results: Our analysis revealed that epigenetic heterogeneity was a key characteristic of IPF AMs. DNAm "clock" analysis indicated that epigenetic alterations in IPF AMs were not associated with accelerated aging. In differential DNAm analysis, we identified numerous differentially methylated positions (n = 11) and differentially methylated regions (n = 49) between healthy and IPF AMs, respectively. Differentially methylated positions and differentially methylated regions encompassed genes involved in lipid (LPCAT1 [lysophosphatidylcholine acyltransferase 1]) and glucose (PFKFB3 [6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3]) metabolism, and importantly, the DNAm status was associated with disease severity in IPF. Conclusions: Collectively, our data identify that changes in the epigenome are associated with the development and function of AMs in the IPF lung.
Entities:
Keywords:
DNA methylation; epigenetics; interstitial lung disease; monocytes; pathogenesis
Authors: Yan Y Sanders; Namasivayam Ambalavanan; Brian Halloran; Xiangyu Zhang; Hui Liu; David K Crossman; Molly Bray; Kui Zhang; Victor J Thannickal; James S Hagood Journal: Am J Respir Crit Care Med Date: 2012-06-14 Impact factor: 21.405
Authors: Luca Richeldi; Christopher J Ryerson; Joyce S Lee; Paul J Wolters; Laura L Koth; Brett Ley; Brett M Elicker; Kirk D Jones; Talmadge E King; Jay H Ryu; Harold R Collard Journal: Thorax Date: 2012-03-17 Impact factor: 9.139
Authors: David A Armstrong; Youdinghuan Chen; John A Dessaint; Daniel S Aridgides; Jacqueline Y Channon; Diane L Mellinger; Brock C Christensen; Alix Ashare Journal: Immunohorizons Date: 2019-07-02
Authors: Giulia Maria Stella; Vito D'Agnano; Davide Piloni; Laura Saracino; Sara Lettieri; Francesca Mariani; Andrea Lancia; Chandra Bortolotto; Pietro Rinaldi; Francesco Falanga; Cristiano Primiceri; Angelo Guido Corsico; Andrea Bianco Journal: Transl Lung Cancer Res Date: 2022-03
Authors: Laura Bergantini; Alessandro Mainardi; Miriana d'Alessandro; Paolo Cameli; David Bennett; Elena Bargagli; Piersante Sestini Journal: Front Pharmacol Date: 2022-03-04 Impact factor: 5.810